Mark Schoenebaum

Biotech stocks are in the midst of an "epic" selloff, Evercore ISI Mark Schoenebaum told CNBC on Monday. Schoenebaum is known for his coverage of big pharma, including Gilead Sciences, Inc. (NASDAQ: GILD), Biogen Inc (NASDAQ: BIIB), Pfizer (NYSE: PFE) and AbbVie Inc (NYSE: ABBV)....

Shares of Regeneron Pharmaceuticals Inc (NASDAQ: REGN) were up more than 5 percent on Tuesday after the company reported earnings of $2.89 per share on revenue of $998.62 million. The second-quarter results surpassed the Street’s consensus estimates, which called for EPS of $2.68 on...

Shares of Zoetis Inc (NYSE: ZTS) were slightly up on Tuesday after the company beat the Street’s consensus estimates on both the earnings and revenue front. Earnings came in at $0.43 per share, versus experts’ expectations for $0.38 per share; Revenue reached $1.175 billion,...

Celgene Corporation (NASDAQ: CELG) reported its second quarter financial results before the market opened. Earnings came in at $1.23 per share on revenue of $2.278 billion, ahead of the Street’s consensus of $1.17 per share and $2.271 billion. Following the earnings call, Evercore ISI...

In a new presentation, Evercore ISI analyst Mark Schoenebaum breaks down the recently announced Celgene Corporation (NASDAQ: CELG) buyout of Receptos Inc (NASDAQ: RCPT). The deal is valued at about $7.2 billion, and the $232/share price that Celgene is paying represents about a 12 percent premium...

In a report published Friday, Evercore ISI analyst Mark Schoenebaum mentioned that the Orkambi approval ROW of Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) is on track with the EMA approval expected later in 2015. According to the Evercore ISI report, "Royalties… Will move into low double...

Last Friday, Amgen, Inc. (NASDAQ: AMGN) filed an intellectual property rights (IPR) suit against AbbVie Inc (NYSE: ABBV)’s 8,916,157 patent, which claims an innovative formulation for Humira. According to IPR timelines, AbbVie should file a response to Amgen’s petition in three...

Bristol-Myers Squibb Co (NYSE: BMY) announced on Fridady that its Opdivo trial was stopped early after superior results. Mark Schoenebaum at Evercore ISI said that expectations "were high going into the interim analysis," but the announcement removes any risk, however small. With the...

Gilead Sciences, Inc. (NASDAQ: GILD), expected to post results after the bell Tuesday, remains a darling on Wall Street after fears of a price war for its Sovaldi hepatitis C treatment receded last month. Investors will be looking for the company's estimate of sales related to hepatitis C...

AbbVie Inc's (NYSE: ABBV) agreement to be the exclusive hepatitis C treatment supplier to pharmacy benefits manager Express Scripts Holding Company (NASDAQ: ESRX) affects up to about 160,000 people in the U.S. suffering from the disease, according to calculations an analyst offered...

ISI analyst Mark Schoenebaum says Pfizer's (NYSE: PFE) final offer is in AstraZeneca (NYSE: AZN) shareholders' hands, calling it "effectively a 'hostile' tender offer." Pfizer on Sunday announced a fourth and final proposal of $92.53, or £55 per share. The press release states, "This proposal...